These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer]. Lind P; Igerc I; Kohlfürst S Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998 [TBL] [Abstract][Full Text] [Related]
4. [Main trends and controversies in treatment of patients with diffuse toxic goiter and thyroid gland cancer]. Romanchishen AF; Vabalaĭte KV Vestn Khir Im I I Grek; 2011; 170(3):58-63. PubMed ID: 21848241 [No Abstract] [Full Text] [Related]
5. Measurement of stimulating TSH receptor antibodies in sera of patients with Graves' disease by a recombinant TSH receptor bioassay. Derwahl M; Schatz H; Bolle B; Pohl A; Meyer K Exp Clin Endocrinol; 1992; 100(1-2):75-9. PubMed ID: 1361452 [No Abstract] [Full Text] [Related]
6. Effect of recombinant human TSH on the uptake of radioactive iodine ((123)I) by the thyroid gland in healthy beagles. Campos M; Peremans K; Duchateau L; Dobbeleir A; Vandermeulen E; van Hoek I; Paes G; Daminet S Domest Anim Endocrinol; 2010 Nov; 39(4):215-21. PubMed ID: 20688462 [TBL] [Abstract][Full Text] [Related]
7. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy. Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164 [TBL] [Abstract][Full Text] [Related]
8. A prospective study of the changes in thyrotropin binding inhibitory immunoglobulins in Graves' disease treated by subtotal thyroidectomy or radioactive iodine. Teng CS; Yeung RT; Khoo RK; Alagaratnam TT J Clin Endocrinol Metab; 1980 Jun; 50(6):1005-10. PubMed ID: 6103007 [TBL] [Abstract][Full Text] [Related]
9. Radioiodine treatment for malignant thyroid disease. Berg G Acta Oncol; 2006; 45(8):1041-5. PubMed ID: 17118836 [TBL] [Abstract][Full Text] [Related]
10. Identification of separate determinants on the thyrotropin receptor reactive with Graves' thyroid-stimulating antibodies and with thyroid-stimulating blocking antibodies in idiopathic myxedema: these determinants have no homologous sequence on gonadotropin receptors. Kosugi S; Ban T; Akamizu T; Kohn LD Mol Endocrinol; 1992 Feb; 6(2):168-80. PubMed ID: 1349156 [TBL] [Abstract][Full Text] [Related]
13. Thyroid cancer. Carling T; Udelsman R Annu Rev Med; 2014; 65():125-37. PubMed ID: 24274180 [TBL] [Abstract][Full Text] [Related]
14. Production of non-stimulatory immunoglobulins that inhibit TSH binding in Graves' disease after radioiodine administration. Bech K; Bliddal H; Siersbaek-Nielsen K; Friis T Clin Endocrinol (Oxf); 1982 Oct; 17(4):395-402. PubMed ID: 6128089 [No Abstract] [Full Text] [Related]
15. Encapsulated insular carcinoma of the thyroid arising in graves' disease: report of a case and review of the literature. Foroughi F; Saadat N; Salehian MT Int J Surg Pathol; 2012 Dec; 20(6):636-9. PubMed ID: 22689614 [TBL] [Abstract][Full Text] [Related]
16. Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves' disease by radioactive iodine. Hamdy O; Raafat S; Saleh GA; Atallah K; M Saleh M; Shebl AM; Hegazy MA Ann R Coll Surg Engl; 2019 May; 101(5):e122-e124. PubMed ID: 30854863 [TBL] [Abstract][Full Text] [Related]
17. Radioiodine therapy for hyperthyroidism. Ross DS N Engl J Med; 2011 Feb; 364(6):542-50. PubMed ID: 21306240 [No Abstract] [Full Text] [Related]
18. Qualitative and quantitative impact of protective glucocorticoid therapy on the effective 131I half-life in radioiodine therapy for Graves disease. Hautzel H; Pisar E; Yazdan-Doust N; Schott M; Beu M; Müller HW J Nucl Med; 2010 Dec; 51(12):1917-22. PubMed ID: 21078788 [TBL] [Abstract][Full Text] [Related]
19. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499 [TBL] [Abstract][Full Text] [Related]
20. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]